Microba Life Sciences (MAP) Q3 2025 earnings summary

Executive summary

• Achieved strong growth in diagnostic test sales and clinical adoption in Australia and the UK, with MetaExplore/MetaXplore and MetaPanel driving momentum and a strategic focus on core diagnostic products.

• Announced landmark clinical study results for MetaPanel in inflammatory bowel disease, leading to major partnerships with leading gastroenterology clinics and integration into routine care.

• Transitioned therapeutics business to a capital-light, partnering-focused, and revenue-driven model, targeting non-dilutive funding for live biotherapeutics and next-generation probiotics.

• Completed transfer/divestment of non-core research services, focusing future revenue on diagnostics and supplements.

Financial highlights

• FY25 full-year revenue guidance of AUD $15.25–16.25 million, representing 26–34% year-over-year growth.

• Q3 FY25 unaudited revenue was $3.43m, down 14% vs PCP due to research services transition; core Personal Testing and Supplements revenue grew 3.5% YoY to $3.3m.

• Record March sales for MetaExplore/MetaXplore and MetaPanel in Australia; MetaXplore UK sales up 1,018% vs PCP, now 39% of UK GI test sales.

• Cash and equivalents at 31 March 2025 totaled $12.41m.

Outlook and guidance

• Forecasts strong Q4 and continued robust growth for the full year, with full market access for MetaXplore in the UK expected by end of June 2025.

• US market entry strategy progressing, starting with a cash-pay model and initial hires planned before end of 2025.